Shiwei Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shiwei Zhu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Liping Duan
Department of Gastroenterology, Peking University Third Hospital , Beijing , China
4 shared publications - Meibo He
Peking University Medical Press, China
4 shared publications - Hui Wei
Department of Gastroenterology, Peking University Third Hospital, Haidian District, Beijing 100191, China
3 shared publications - Jindong Zhang
Department of Gastroenterology, Peking University Third Hospital , Beijing 100191 , China
3 shared publications - Qinghua Sun
School of Public Health, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou 310053, Zhejiang Province, China
3 shared publications - Zuojing Liu
Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in European Journal of Medical Research
Acute kidney injury in pancreatitis: association and predictive value of composite inflammatory indices
Objectives: To investigate the associations of composite inflammatory indices with acute kidney injury (AKI) and hospital mortality in patients with pancreatitis, and to evaluate their incremental value in AKI prediction models. Methods: This retrospective cohort study included patients with pancreatitis admitted to the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The associations of composite inflammatory indices, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), with AKI and hospital mortality were evaluated. An AKI prediction model was developed based on clinical variables and inflammatory indices, and its performance was assessed using receiver operating characteristic (ROC) curves, calibration analysis, and decision curve analysis. External validation was performed using the eICU Collaborative Research Database (eICU–CRD) cohort. Results: A total of 646 patients from the MIMIC-IV cohort were included, with 319 (68.02%) developing AKI. Composite inflammatory indices showed limited predictive performance for AKI when used alone. The integrated prediction model combining inflammatory indices and clinical variables showed acceptable discrimination in the MIMIC-IV cohort (AUC = 0.654, 95% CI 0.602–0.706) and was externally validated in the eICU–CRD cohort (AUC = 0.658, 95% CI 0.608–0.708). RCS analysis showed no significant associations between inflammatory indices and AKI, while PLR showed a significant nonlinear association with hospital mortality only in the eICU–CRD cohort. Conclusions: Composite inflammatory indices alone showed limited discrimination for AKI prediction, whereas their integration with clinical variables improved discrimination compared with inflammatory indices alone, although no significant incremental benefit was observed over clinical variables alone. The developed model may provide a useful tool for early identification of patients at higher risk of AKI in pancreatitis.
- 13 November 2026
- Published by Springer Nature in European Journal of Medical Research
Open AccessAcute kidney injury in pancreatitis: association and predictive value of composite inflammatory indices
Objectives: To investigate the associations of composite inflammatory indices with acute kidney injury (AKI) and hospital mortality in patients with pancreatitis, and to evaluate their incremental value in AKI prediction models. Methods: This retrospective cohort study included patients with pancreatitis admitted to the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The associations of composite inflammatory indices, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), with AKI and hospital mortality were evaluated. An AKI prediction model was developed based on clinical variables and inflammatory indices, and its performance was assessed using receiver operating characteristic (ROC) curves, calibration analysis, and decision curve analysis. External validation was performed using the eICU Collaborative Research Database (eICU–CRD) cohort. Results: A total of 646 patients from the MIMIC-IV cohort were included, with 319 (68.02%) developing AKI. Composite inflammatory indices showed limited predictive performance for AKI when used alone. The integrated prediction model combining inflammatory indices and clinical variables showed acceptable discrimination in the MIMIC-IV cohort (AUC = 0.654, 95% CI 0.602–0.706) and was externally validated in the eICU–CRD cohort (AUC = 0.658, 95% CI 0.608–0.708). RCS analysis showed no significant associations between inflammatory indices and AKI, while PLR showed a significant nonlinear association with hospital mortality only in the eICU–CRD cohort. Conclusions: Composite inflammatory indices alone showed limited discrimination for AKI prediction, whereas their integration with clinical variables improved discrimination compared with inflammatory indices alone, although no significant incremental benefit was observed over clinical variables alone. The developed model may provide a useful tool for early identification of patients at higher risk of AKI in pancreatitis.
- Open Access
- 25 August 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (14) , 1716-1727
Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
Background: As a non-invasive and effective diagnostic method for small intestinal bacterial overgrowth (SIBO), wild-use of breath test (BT) has demonstrated a high comorbidity rate in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and SIBO. Patients overlapping with SIBO respond better to rifaximin therapy than those with IBS-D only. Gut microbiota plays a critical role in both of these two diseases. We aimed to determine the microbial difference between IBS-D overlapping with/without SIBO, and to study the underlying mechanism of its sensitivity to rifaximin. Methods: Patients with IBS-D were categorized as BT-negative (IBSN) and BT-positive (IBSP). Healthy volunteers (BT-negative) were enrolled as healthy control. The patients were clinically evaluated before and after rifaximin treatment (0.4 g bid, 4 weeks). Blood, intestine, and stool samples were collected for cytokine assessment and gut microbial analyses. Results: Clinical complaints and microbial abundance were significantly higher in IBSP than in IBSN. In contrast, severe systemic inflammation and more active bacterial invasion function that were associated with enrichment of opportunistic pathogens were seen in IBSN. The symptoms of IBSP patients were relieved in different degrees after therapy, but the symptoms of IBSN rarely changed. We also found that the presence of IBSN-enriched genera (Enterobacter and Enterococcus) are unaffected by rifaximin therapy. Conclusions: IBS-D patients overlapping with SIBO showed noticeably different fecal microbial composition and function compared with IBS-D only. The better response to rifaximin in those comorbid patients might associate with their different gut microbiota, which suggests that BT is necessary before IBS-D diagnosis and use of rifaximin. Registration: Chinese Clinical Trial Registry, ChiCTR1800017911.
- 25 August 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (14) , 1716-1727
Open AccessPatients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
Background: As a non-invasive and effective diagnostic method for small intestinal bacterial overgrowth (SIBO), wild-use of breath test (BT) has demonstrated a high comorbidity rate in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and SIBO. Patients overlapping with SIBO respond better to rifaximin therapy than those with IBS-D only. Gut microbiota plays a critical role in both of these two diseases. We aimed to determine the microbial difference between IBS-D overlapping with/without SIBO, and to study the underlying mechanism of its sensitivity to rifaximin. Methods: Patients with IBS-D were categorized as BT-negative (IBSN) and BT-positive (IBSP). Healthy volunteers (BT-negative) were enrolled as healthy control. The patients were clinically evaluated before and after rifaximin treatment (0.4 g bid, 4 weeks). Blood, intestine, and stool samples were collected for cytokine assessment and gut microbial analyses. Results: Clinical complaints and microbial abundance were significantly higher in IBSP than in IBSN. In contrast, severe systemic inflammation and more active bacterial invasion function that were associated with enrichment of opportunistic pathogens were seen in IBSN. The symptoms of IBSP patients were relieved in different degrees after therapy, but the symptoms of IBSN rarely changed. We also found that the presence of IBSN-enriched genera (Enterobacter and Enterococcus) are unaffected by rifaximin therapy. Conclusions: IBS-D patients overlapping with SIBO showed noticeably different fecal microbial composition and function compared with IBS-D only. The better response to rifaximin in those comorbid patients might associate with their different gut microbiota, which suggests that BT is necessary before IBS-D diagnosis and use of rifaximin. Registration: Chinese Clinical Trial Registry, ChiCTR1800017911.
- Open Access
- 1 March 2021
- Published by Elsevier in Pharmacological Research
- Vol. 165, 105439
Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota
- 1 March 2021
- Published by Elsevier in Pharmacological Research
- Vol. 165, 105439
Open AccessBerberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota
- Open Access
- 17 February 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 18 (6) , 708-720
Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis
Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis of irritable bowel syndrome (IBS). Melatonin plays a beneficial role in gut motility and immunity. However, altered expression of local mucosal melatonin in IBS and its relationship with the gut microbiota remain unclear. Therefore, we aimed to detect the colonic melatonin levels and microbiota profiles in patients with diarrhea-predominant IBS (IBS-D) and explore their relationship in germ-free (GF) rats and BON-1 cells. Thirty-two IBS-D patients and twenty-eight healthy controls (HCs) were recruited. Fecal specimens from IBS-D patients and HCs were separately transplanted into GF rats by gavage. The levels of colon mucosal melatonin were assessed by immunohistochemical methods, and fecal microbiota communities were analyzed using 16S rDNA sequencing. The effect of butyrate on melatonin synthesis in BON-1 cells was evaluated by ELISA. Melatonin levels were significantly increased and negatively correlated with visceral hypersensitivity in IBS-D patients. GF rats inoculated with fecal microbiota from IBS-D patients had high colonic melatonin levels. Butyrate-producing Clostridium cluster XIVa species, such as Roseburia species and Lachnospira species, were positively related to colonic mucosal melatonin expression. Butyrate significantly increased melatonin secretion in BON-1 cells. Increased melatonin expression may be an adaptive protective mechanism in the development of IBS-D. Moreover, some Clostridium cluster XIVa species could increase melatonin expression via butyrate production. Modulation of the gut hormone/gut microbiota axis offers a promising target of interest for IBS in the future.
- 17 February 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 18 (6) , 708-720
Open AccessIncreased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis
Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis of irritable bowel syndrome (IBS). Melatonin plays a beneficial role in gut motility and immunity. However, altered expression of local mucosal melatonin in IBS and its relationship with the gut microbiota remain unclear. Therefore, we aimed to detect the colonic melatonin levels and microbiota profiles in patients with diarrhea-predominant IBS (IBS-D) and explore their relationship in germ-free (GF) rats and BON-1 cells. Thirty-two IBS-D patients and twenty-eight healthy controls (HCs) were recruited. Fecal specimens from IBS-D patients and HCs were separately transplanted into GF rats by gavage. The levels of colon mucosal melatonin were assessed by immunohistochemical methods, and fecal microbiota communities were analyzed using 16S rDNA sequencing. The effect of butyrate on melatonin synthesis in BON-1 cells was evaluated by ELISA. Melatonin levels were significantly increased and negatively correlated with visceral hypersensitivity in IBS-D patients. GF rats inoculated with fecal microbiota from IBS-D patients had high colonic melatonin levels. Butyrate-producing Clostridium cluster XIVa species, such as Roseburia species and Lachnospira species, were positively related to colonic mucosal melatonin expression. Butyrate significantly increased melatonin secretion in BON-1 cells. Increased melatonin expression may be an adaptive protective mechanism in the development of IBS-D. Moreover, some Clostridium cluster XIVa species could increase melatonin expression via butyrate production. Modulation of the gut hormone/gut microbiota axis offers a promising target of interest for IBS in the future.
- Open Access
Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis
Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis of irritable bowel syndrome (IBS). Melatonin plays a beneficial role in gut motility and immunity. However, altered expression of local mucosal melatonin in IBS and its relationship with the gut microbiota remain unclear. Therefore, we aimed to detect the colonic melatonin levels and microbiota profiles in patients with diarrhea-predominant IBS (IBS-D) and explore their relationship in germ-free (GF) rats and BON-1 cells. Thirty-two IBS-D patients and twenty-eight healthy controls (HC) were recruited. Fecal specimens from IBS-D patients and HCs were separately transplanted into GF rats by gavage. The levels of colon mucosal melatonin were assessed by immunohistochemical methods, and fecal microbiota communities were analyzed using 16S rDNA sequencing. The effect of butyrate on melatonin synthesis in BON-1 cells was evaluated by ELISA. Melatonin levels were significantly increased in IBS-D patients compared with HC and were significantly negatively correlated with visceral sensitivity in IBS-D patients. GF rats inoculated with fecal microbiota from IBS-D patients had high colonic melatonin levels. Butyrate-producing Clostridium cluster XIVa species, such as Roseburia species and Lachnospira species, were positively related to colonic mucosal melatonin expression. Butyrate significantly increased melatonin secretion in BON-1 cells. Increased melatonin expression may be an adaptive protective mechanism in the development of IBS-D. Moreover, some Clostridium cluster XIVa species could increase melatonin expression via butyrate production. Modulation of the gut hormone/gut microbiota axis offers a promising target of interest for IBS in the future.
Open AccessIncreased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis
Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis of irritable bowel syndrome (IBS). Melatonin plays a beneficial role in gut motility and immunity. However, altered expression of local mucosal melatonin in IBS and its relationship with the gut microbiota remain unclear. Therefore, we aimed to detect the colonic melatonin levels and microbiota profiles in patients with diarrhea-predominant IBS (IBS-D) and explore their relationship in germ-free (GF) rats and BON-1 cells. Thirty-two IBS-D patients and twenty-eight healthy controls (HC) were recruited. Fecal specimens from IBS-D patients and HCs were separately transplanted into GF rats by gavage. The levels of colon mucosal melatonin were assessed by immunohistochemical methods, and fecal microbiota communities were analyzed using 16S rDNA sequencing. The effect of butyrate on melatonin synthesis in BON-1 cells was evaluated by ELISA. Melatonin levels were significantly increased in IBS-D patients compared with HC and were significantly negatively correlated with visceral sensitivity in IBS-D patients. GF rats inoculated with fecal microbiota from IBS-D patients had high colonic melatonin levels. Butyrate-producing Clostridium cluster XIVa species, such as Roseburia species and Lachnospira species, were positively related to colonic mucosal melatonin expression. Butyrate significantly increased melatonin secretion in BON-1 cells. Increased melatonin expression may be an adaptive protective mechanism in the development of IBS-D. Moreover, some Clostridium cluster XIVa species could increase melatonin expression via butyrate production. Modulation of the gut hormone/gut microbiota axis offers a promising target of interest for IBS in the future.
- Open Access
- 27 January 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41647
Protective effects of recombinant human cytoglobin against chronic alcohol-induced liver disease in vivo and in vitro
Alcoholic liver disease (ALD) is an important worldwide public health issue with no satisfying treatment available since now. Here we explore the effects of recombinant human cytoglobin (rhCygb) on chronic alcohol-induced liver injury and the underlying mechanisms. In vivo studies showed that rhCygb was able to ameliorate alcohol-induced liver injury, significantly reversed increased serum index (ALT, AST, TG, TC and LDL-C) and decreased serum HDL-C. Histopathology observation of the liver of rats treated with rhCygb confirmed the biochemical data. Furthermore, rhCygb significantly inhibited Kupffer cells (KCs) proliferation and TNF-α expression in LPS-induced KCs. rhCygb also inhibited LPS-induced NADPH oxidase activity and ROS, NO and O2•− generation. These results collectively indicate that rhCygb exert the protective effect on chronic alcohol-induced liver injury through suppression of KC activation and oxidative stress. In view of its anti-oxidative stress and anti-inflammatory features, rhCygb might be a promising candidate for development as a therapeutic agent against ALD.
- 27 January 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41647
Open AccessProtective effects of recombinant human cytoglobin against chronic alcohol-induced liver disease in vivo and in vitro
Alcoholic liver disease (ALD) is an important worldwide public health issue with no satisfying treatment available since now. Here we explore the effects of recombinant human cytoglobin (rhCygb) on chronic alcohol-induced liver injury and the underlying mechanisms. In vivo studies showed that rhCygb was able to ameliorate alcohol-induced liver injury, significantly reversed increased serum index (ALT, AST, TG, TC and LDL-C) and decreased serum HDL-C. Histopathology observation of the liver of rats treated with rhCygb confirmed the biochemical data. Furthermore, rhCygb significantly inhibited Kupffer cells (KCs) proliferation and TNF-α expression in LPS-induced KCs. rhCygb also inhibited LPS-induced NADPH oxidase activity and ROS, NO and O2•− generation. These results collectively indicate that rhCygb exert the protective effect on chronic alcohol-induced liver injury through suppression of KC activation and oxidative stress. In view of its anti-oxidative stress and anti-inflammatory features, rhCygb might be a promising candidate for development as a therapeutic agent against ALD.